A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

The FDA has approved the first generic form of liraglutide (Victoza), a once-daily injectable for improving glycemic control ...

Novo Nordisk’s Saxenda has been recommended ... overtaking Novo Nordisk’s older Victoza (liraglutide) product which requires dosing by injection every day. Ozempic is squaring off in the ...

which also sells a version of liraglutide approved for obesity, called Saxenda. “There are many people on this drug, and they will benefit by another generic version of it,” Dr. Harlan ...

liraglutide also underpins Novo’s older weight loss drug Saxenda and its insulin-degludec-based diabetes combination therapy Xultophy. While a newer class of GLP-1s based on Novo’s semaglutide ...

Liraglutide is currently sold only in an injectable form under the brand names Saxenda® and Victoza®, both manufactured by Novo Nordisk. Despite the launch of a genericized version of ...

is pleased to announce the engagement of a contract research organization ("CRO") to design and execute a human pilot study evaluating DehydraTECH-liraglutide against Saxenda® injectable liraglutide.

Novo Nordisk (NVO) markets liraglutide under the brand names Victoza, Saxenda and Xultophy. The drug is currently on the FDA's drug shortage list. Compounding pharmacies are allowed to make ...

(Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of a contract research organization ("CRO") to design and ...

It is expected that the FDA will soon approve this generic as an obesity treatment since the obesity drug Saxenda has the same active ingredient and was released afterward. The generic of Victoza ...